Terms: = Prostate cancer AND Beta-hCG AND Treatment
12 results:
1. Urothelial carcinoma of the prostate with raised β-hCG levels: a case report.
Sołek J; Kalwas M; Sobczak M; Dębska-Szmich S; Kupnicki P; Jesionek-Kupnicka D
J Med Case Rep; 2022 Jun; 16(1):238. PubMed ID: 35701835
[TBL] [Abstract] [Full Text] [Related]
2. Tumour markers and their utility in imaging of abdominal and pelvic malignancies.
Lahoud RM; O'Shea A; El-Mouhayyar C; Atre ID; Eurboonyanun K; Harisinghani M
Clin Radiol; 2021 Feb; 76(2):99-107. PubMed ID: 32861463
[TBL] [Abstract] [Full Text] [Related]
3. Elevated beta human chorionic gonadotropin in a non-pregnant female diagnosed with anal squamous cell carcinoma.
Pokharel K; Gilbar PJ; Mansfield SK; Nair LM; So A
J Oncol Pharm Pract; 2020 Jul; 26(5):1266-1269. PubMed ID: 31840564
[TBL] [Abstract] [Full Text] [Related]
4. Use of common seric tumor markers in patients with solid cancers.
Gara S; Boussen H; Ghanem A; Guemira F
Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
[TBL] [Abstract] [Full Text] [Related]
5. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract] [Full Text] [Related]
6. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract] [Full Text] [Related]
7. [Diagnostic management of inaugurable metastases].
Penel N
Presse Med; 2003 Jun; 32(21):990-6, 1004. PubMed ID: 12876530
[TBL] [Abstract] [Full Text] [Related]
8. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
Canil CM; Tannock IF
Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
[TBL] [Abstract] [Full Text] [Related]
9. TPA, TATI, CEA, AFP, beta-hcg, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract] [Full Text] [Related]
10. Clinical use of tumor markers in oncology.
Jacobs EL; Haskell CM
Curr Probl Cancer; 1991; 15(6):299-360. PubMed ID: 1760927
[TBL] [Abstract] [Full Text] [Related]
11. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
[TBL] [Abstract] [Full Text] [Related]
12. [Peptide hormones LH, FSH, TSH, prolactin, beta-hcg and PTH in patients with urogenital tumors].
Dunzendorfer U; Drahovsky D; Schmidt-Gayk H
Onkologie; 1981 Aug; 4(4):188-92. PubMed ID: 6795555
[TBL] [Abstract] [Full Text] [Related]
